Literature DB >> 26811604

Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis.

Giovanni Brandi1, Stefania De Lorenzo1, Margherita Nannini1, Stefania Curti1, Marta Ottone1, Filippo Gustavo Dall'Olio1, Maria Aurelia Barbera1, Maria Abbondanza Pantaleo1, Guido Biasco1.   

Abstract

Surgical resection is the only option of cure for patients with metastatic colorectal cancer (CRC). However, the risk of recurrence within 18 mo after metastasectomy is around 75% and the liver is the most frequent site of relapse. The current international guidelines recommend an adjuvant therapy after surgical resection of CRC metastases despite the lower level of evidence (based on the quality of studies in this setting). However, there is still no standard treatment and the effective role of an adjuvant therapy remains controversial. The aim of this review is to report the state-of-art of systemic chemotherapy and regional chemotherapy with hepatic arterial infusion in the management of patients after resection of metastases from CRC, with a literature review and meta-analysis of the relevant randomized controlled trials.

Entities:  

Keywords:  Adjuvant chemotherapy; Adjuvant hepatic artery infusion; Colorectal cancer; Liver metastases; Metastasectomy

Mesh:

Substances:

Year:  2016        PMID: 26811604      PMCID: PMC4716056          DOI: 10.3748/wjg.v22.i2.519

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  110 in total

1.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2013-10-11       Impact factor: 41.316

2.  Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.

Authors:  Herbert I Hurwitz; Niall C Tebbutt; Fairooz Kabbinavar; Bruce J Giantonio; Zhong-Zhen Guan; Lada Mitchell; Daniel Waterkamp; Josep Tabernero
Journal:  Oncologist       Date:  2013-07-23

3.  Liver resection for colorectal metastases.

Authors:  Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

4.  Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history.

Authors:  J Scheele; R Stangl; A Altendorf-Hofmann
Journal:  Br J Surg       Date:  1990-11       Impact factor: 6.939

5.  Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.

Authors:  Andreas A Schnitzbauer; Sven A Lang; Holger Goessmann; Silvio Nadalin; Janine Baumgart; Stefan A Farkas; Stefan Fichtner-Feigl; Thomas Lorf; Armin Goralcyk; Rüdiger Hörbelt; Alexander Kroemer; Martin Loss; Petra Rümmele; Marcus N Scherer; Winfried Padberg; Alfred Königsrainer; Hauke Lang; Aiman Obed; Hans J Schlitt
Journal:  Ann Surg       Date:  2012-03       Impact factor: 12.969

6.  Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?

Authors:  Eran Sadot; Bas Groot Koerkamp; Julie N Leal; Jinru Shia; Mithat Gonen; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Nancy Kemeny; Leslie H Blumgart; William R Jarnagin; Michael I DʼAngelica
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

7.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

8.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

Authors:  Eric Van Cutsem; Roberto Labianca; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Claire Topham; Josep Tabernero; Thierry André; Alberto F Sobrero; Enrico Mini; Richard Greil; Francesco Di Costanzo; Laurence Collette; Laura Cisar; Xiaoxi Zhang; David Khayat; Carsten Bokemeyer; Arnaud D Roth; David Cunningham
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

9.  Impact of type of liver resection on the outcome of colorectal liver metastases: a case-matched analysis.

Authors:  Eleonora Guzzetti; Carlo Pulitanò; Marco Catena; Marcella Arru; Francesca Ratti; Renato Finazzi; Luca Aldrighetti; Gianfranco Ferla
Journal:  J Surg Oncol       Date:  2008-05-01       Impact factor: 3.454

10.  Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

Authors:  Eduardo Díaz-Rubio; Jose Tabernero; Auxiliadora Gómez-España; Bartomeu Massutí; Javier Sastre; Manuel Chaves; Alberto Abad; Alfredo Carrato; Bernardo Queralt; Juan José Reina; Joan Maurel; Encarnación González-Flores; Jorge Aparicio; Fernando Rivera; Ferrán Losa; Enrique Aranda
Journal:  J Clin Oncol       Date:  2007-06-04       Impact factor: 44.544

View more
  32 in total

1.  Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018.

Authors:  A J Hyde; R Nassabein; A AlShareef; D Armstrong; S Babak; S Berry; D Bossé; E Chen; B Colwell; C Essery; R Goel; R Goodwin; S Gray; N Hammad; A Jeyakuymar; D Jonker; P Karanicolas; N Lamond; R Letourneau; J Michael; N Patil; E Powell; R Ramjeesingh; W Saliba; R Singh; S Snow; T Stuckless; S Tadros; M Tehfé; M Thana; M Thirlwell; M Vickers; K Virik; S Welch; T Asmis
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

2.  Prognostic significance of primary tumor sidedness in patients undergoing liver resection for metastatic colorectal cancer.

Authors:  Emily K Elizabeth McCracken; Gregory P Samsa; Deborah A Fisher; Norma E Farrow; Karenia Landa; Kevin N Shah; Dan G Blazer; Sabino Zani
Journal:  HPB (Oxford)       Date:  2019-05-30       Impact factor: 3.647

3.  Vitamin D Deficiency has a Negative Impact on Cetuximab-Mediated Cellular Cytotoxicity against Human Colon Carcinoma Cells.

Authors:  Lorenzo Mortara; Marzia B Gariboldi; Annalisa Bosi; Marco Bregni; Graziella Pinotti; Luigina Guasti; Alessandro Squizzato; Douglas M Noonan; Elena Monti; Leonardo Campiotti
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

Review 4.  PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system.

Authors:  L Alonso-Alconada; J Barbazan; S Candamio; J L Falco; C Anton; C Martin-Saborido; G Fuster; M Sampedro; C Grande; R Lado; L Sampietro-Colom; E Crego; S Figueiras; L Leon-Mateos; R Lopez-Lopez; M Abal
Journal:  Clin Transl Oncol       Date:  2017-10-20       Impact factor: 3.405

5.  Parenchymal-sparing hepatectomies (PSH) for bilobar colorectal liver metastases are associated with a lower morbidity and similar oncological results: a propensity score matching analysis.

Authors:  Riccardo Memeo; Vito de Blasi; René Adam; Diane Goéré; Daniel Azoulay; Ahmet Ayav; Emilie Gregoire; Reza Kianmanesh; Francis Navarro; Antonio Sa Cunha; Patrick Pessaux
Journal:  HPB (Oxford)       Date:  2016-07-05       Impact factor: 3.647

Review 6.  Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer: Lessons Learned and Future Perspectives.

Authors:  Maria C Riesco-Martinez; Andrea Modrego; Paula Espinosa-Olarte; Anna La Salvia; Rocio Garcia-Carbonero
Journal:  Curr Treat Options Oncol       Date:  2022-08-18

7.  Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases.

Authors:  Toshiaki Yoshimoto; Yuji Morine; Satoru Imura; Tetsuya Ikemoto; Syuichi Iwahashi; Y U Saito; Sinichiro Yamada; Daichi Ishikawa; Hiroki Teraoku; Masato Yoshikawa; Jun Higashijima; Chie Takasu; Mitsuo Shimada
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

8.  A Prognostic Nomogram of Colon Cancer With Liver Metastasis: A Study of the US SEER Database and a Chinese Cohort.

Authors:  Chuan Liu; Chuan Hu; Jiale Huang; Kanghui Xiang; Zhi Li; Jinglei Qu; Ying Chen; Bowen Yang; Xiujuan Qu; Yunpeng Liu; Guangwei Zhang; Ti Wen
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

9.  Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.

Authors:  Yamila Sol Rocca; María Paula Roberti; Estefanía Paula Juliá; María Betina Pampena; Luisina Bruno; Sergio Rivero; Eduardo Huertas; Fernando Sánchez Loria; Alejandro Pairola; Anne Caignard; José Mordoh; Estrella Mariel Levy
Journal:  Front Immunol       Date:  2016-10-10       Impact factor: 7.561

10.  Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts.

Authors:  Stephanie J Blocker; Kirk A Douglas; Lisa Anne Polin; Helen Lee; Bart S Hendriks; Enxhi Lalo; Wei Chen; Anthony F Shields
Journal:  Theranostics       Date:  2017-09-26       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.